A recent Phase I/II study of DSF and Cu++ with concurrent radiation therapy and TMZ for newly diagnosed glioblastoma demonstrated promising preliminary efficacy for a subset of tumors with IDH1, BRAF, and NF1 mutations [32]. This evidence concerns the gene BRAF and glioblastoma.